Scaling N-of-1 Therapies to Viability

Kent Rogers, CEO of EveryONE Medicines, discusses the challenges of building a sustainable business model for the development of individualized therapies, the regulatory hurdles it may face, and what it will take to get payers to embrace such medicines.